=== PAGE 2 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Kimberly Skopitz
Kowa Pharmaceuticals America, Inc.
NDA 022363 MA 609

                                                                                                       Page 2

LIVALO® is indicated as an adjunctive therapy to diet to reduce elevated total
cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo
B), triglycerides (TG), and to increase HDL-C in adult patients with primary
hyperlipidemia or mixed dyslipidemia.

<u>Limitations of Use</u>

Doses of LIVALO greater than 4 mg once daily were associated with an increased
risk for severe myopathy in premarketing clinical studies. Do not exceed 4 mg once
daily dosing of LIVALO.

The effect of LIVALO on cardiovascular morbidity and mortality has not been
determined.

LIVALO has not been studied in Fredrickson Type I, III, and V dyslipidemias.

This product is associated with a number of serious risks. Livalo is contraindicated in
patients with known hypersensitivity to any component of the product, active liver disease
which may include unexplained persistent elevations of hepatic transaminase levels, co-
administration with cyclosporine, and in patients who are pregnant or lactating. The PI for
Livalo contains warnings and precautions regarding skeletal muscle effects, liver enzyme
abnormalities, and endocrine function. The most common adverse reactions reported with
Livalo were myalgia, back pain, diarrhea, constipation and pain in extremity.

**False or Misleading Risk Presentations**

Promotional materials misbrand a drug if they are false or misleading with respect to risk.
The determination of whether promotional materials are misleading includes, among other
things, not only representations made or suggested in promotional materials, but also failure
to reveal facts material in light of the representations made or with with respect to consequences
that may result from the use of the drug as recommended or suggested in the materials.

The video includes patient testimonials such as the following (emphasis original):

<u>**Debbie D.**</u>

VOICEOVER (VO) (:04 - :06): “When I did the cholesterol panel, mine was extremely
high.”
SUPER: **my** switch to LIVALO®
               Debbie D. Switched statins 6 times due to side effects

VO (:45 - :48): “After I took LIVALO, I’ve had no pain and my cholesterol levels are
down.”
SUPER: **my** switch to LIVALO®
               Debbie D. Taking LIVALO for 3 years

Reference ID: 4496702
